Local Institution
New Delhi 116025
0 studies enrolling now · 15 studies all time
What they study most
Acute Coronary Syndrome, Acute Coronary Syndromes, Atrial Fibrillation, Atrial Flutter, Bipolar Disorder, Chronic Hepatitis B, Chronic Kidney Failure, Hepatitis B, Hepatitis B, Chronic, Hepatitis C Virus (HCV), Hepato Cellular Carcinoma (HCC), Kidney Transplantation
Studies at this site
- A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania — Completed
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
- A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
- Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
- Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
- First Line Hepato Cellular Carcinoma (HCC) — Completed
- Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
- Phase III Acute Coronary Syndrome — Stopped early
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
- Methotrexate-Inadequate Response Study — Completed
- Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus — Completed
- Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation — Completed
- Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C — Withdrawn before enrolling
- Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes — Completed